Debra S. Brandt - Jupiter Medical ...

Dr. Debra S. Brandt

Claim this profile

Jupiter Medical Center

Studies Breast Cancer
Studies Breast cancer
9 reported clinical trials
21 drugs studied

Area of expertise

1

Breast Cancer

Debra S. Brandt has run 4 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive
2

Breast Cancer

Debra S. Brandt has run 3 trials for Breast cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive

Affiliated Hospitals

Image of trial facility.

Jupiter Medical Center

Image of trial facility.

Smilow Cancer Hospital Care Center-Fairfield

Clinical Trials Debra S. Brandt is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

More about Debra S. Brandt

Clinical Trial Related

2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Debra S. Brandt has experience with

  • Paclitaxel
  • Carboplatin
  • Cyclophosphamide
  • Durvalumab
  • Stereotactic Body Radiation Therapy
  • Doxorubicin Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Debra S. Brandt specialize in?

Is Debra S. Brandt currently recruiting for clinical trials?

Are there any treatments that Debra S. Brandt has studied deeply?

What is the best way to schedule an appointment with Debra S. Brandt?

What is the office address of Debra S. Brandt?

Is there any support for travel costs?